RBC Capital raised the firm’s price target on Boston Scientific (BSX) to $120 from $116 and keeps an Outperform rating on the shares. The company reported impressive Q1 results, and the firm sees Boston Scientific as among the highest performing MedTech large-caps this year and beyond, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific price target lowered to $121 from $122 at Raymond James
- Boston Scientific price target raised to $120 from $115 at Baird
- Boston Scientific’s Strong Q1 2025 Performance and Strategic Positioning Justify Buy Rating
- Boston Scientific’s Strong Q1 2025 Performance and Growth Potential Justifies Buy Rating
- Boston Scientific: Strong Financial Performance and Positive Outlook Support Buy Rating